Physician profile
Ramesh Kesavalu
NPI 1932147626
$29,805.52
in general payments reported to CMS, 2019-2025
31 companies · $1,508 in 2025
The $1,508 reported for 2025 was more than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,985 · 2020: $1,662 · 2021: $1,455 · 2022: $5,021 · 2023: $15K · 2024: $1,714 · 2025: $1,508.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Honoraria: $11K · Food and Beverage: $5,685 · Travel and Lodging: $2,283 · Education: $115.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Honoraria | $10,600.00 |
| Food and Beverage | $5,685.33 |
| Travel and Lodging | $2,282.78 |
| Education | $114.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aurinia Pharma U.S., INC. | $13,519.46 | 2021-2024 | Lupkynis |
| Amgen INC. | $3,042.34 | 2019-2025 | Enbrel, Tavneos, Otezla |
| Abbvie INC. | $2,855.03 | 2019-2025 | |
| Octapharma USA, INC. | $2,610.94 | 2021-2024 | Octagam Immune Globulin (Human) |
| Glaxosmithkline, LLC. | $1,429.67 | 2019-2025 | Benlysta |
| Horizon Therapeutics Plc | $1,281.12 | 2019-2020 | |
| Mallinckrodt Hospital Products INC. | $844.22 | 2021-2025 | Acthar |
| Novartis Pharmaceuticals Corporation | $700.40 | 2019-2025 | |
| Ucb, INC. | $540.91 | 2019-2025 | Cimzia, Bimzelx |
| Lilly USA, LLC | $373.94 | 2019-2022 | |
| Janssen Biotech, INC. | $366.87 | 2021-2024 | Tremfya |
| Genzyme Corporation | $331.77 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $288.30 | 2022-2025 | Saphnelo |
| Pfizer INC. | $283.43 | 2019-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $257.34 | 2019-2025 | Jardiance, Cyltezo, Ofev |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $163.55 | 2019 | |
| Fresenius Kabi USA, LLC | $138.71 | 2023-2024 | Idacio, Tyenne |
| E.R. Squibb & Sons, L.L.C. | $125.00 | 2021 | |
| Alexion Pharmaceuticals, INC. | $103.64 | 2023-2025 | Strensiq |
| Radius Health, INC. | $102.50 | 2021-2022 | |
| Ani Pharmaceuticals, INC. | $99.16 | 2022-2025 | Purified Cortrophin Gel |
| Genentech USA, INC. | $98.34 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $38.90 | 2019 | |
| Vertiflex, INC. | $36.20 | 2019 | |
| Ultragenyx Pharmaceutical INC. | $35.35 | 2021-2023 | |
| Stryker Corporation | $35.20 | 2022 | |
| Mallinckrodt Enterprises LLC | $27.78 | 2019 | |
| Merck Sharp & Dohme LLC | $21.23 | 2025 | Capvaxive, Gardasil 9 |
| Boston Scientific Corporation | $20.84 | 2024 | Watchman Flx |
| Novo Nordisk INC | $18.34 | 2021 | |
| Celltrion USA INC. | $15.04 | 2023 | Yuflyma |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ramesh Kesavalu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.